Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage radiopharma company, has regained compliance with Nasdaq's minimum bid price requirement. The company received notice from Nasdaq that it has met the listing rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for at least 10 consecutive trading sessions. This development ensures Monopar's continued listing on the Nasdaq stock exchange, maintaining its visibility and access to capital markets. The compliance status is important for the company's ongoing efforts in developing innovative cancer treatments.
Monopar Therapeutics (Nasdaq: MNPR), un'azienda radioterapica in fase clinica, ha riacquisito la conformità con il requisito di prezzo minimo per le offerte di Nasdaq. L'azienda ha ricevuto notifica da Nasdaq di aver soddisfatto la regola di quotazione 5550(a)(2), che richiede un prezzo minimo per offerta di $1,00 per azione per almeno 10 sessioni di trading consecutive. Questo sviluppo assicura il continuo mantenimento della società sulla borsa Nasdaq, preservando la sua visibilità e accesso ai mercati dei capitali. Lo stato di conformità è importante per gli sforzi dell'azienda nel sviluppare trattamenti innovativi contro il cancro.
Monopar Therapeutics (Nasdaq: MNPR), una empresa de radioterapia en fase clínica, ha recuperado la conformidad con el requisito de precio mínimo de oferta de Nasdaq. La empresa recibió un aviso de Nasdaq indicando que ha cumplido con la regla de cotización 5550(a)(2), que exige un precio mínimo de oferta de $1.00 por acción durante al menos 10 sesiones de negociación consecutivas. Este desarrollo garantiza la continuidad de la cotización de Monopar en la bolsa de Nasdaq, manteniendo su visibilidad y acceso a los mercados de capital. El estado de conformidad es importante para los esfuerzos continuos de la empresa en el desarrollo de tratamientos innovadores contra el cáncer.
Monopar Therapeutics (Nasdaq: MNPR)는 임상 단계의 방사선 제약 회사로, Nasdaq의 최소 입찰 가격 요구 사항을 재차 승인 받았습니다. 회사는 Nasdaq으로부터 최소 입찰 가격이 $1.00 주당 10일 연속 거래 세션 이상 지속됨을 요구하는 상장 규칙 5550(a)(2)를 충족했다는 통지를 받았습니다. 이 발전은 Monopar가 Nasdaq 증권 거래소의 상장을 지속할 수 있도록 보장하며, 이는 자본 시장에서의 가시성과 접근성을 유지하게 됩니다. 준수 상태는 회사의 혁신적인 암 치료 개발에 대한 지속적인 노력에 중요합니다.
Monopar Therapeutics (Nasdaq: MNPR), une entreprise de radiopharmaceutique en phase clinique, a récupéré sa conformité aux exigences de prix minimum de Nasdaq. L'entreprise a reçu une notification de Nasdaq indiquant qu'elle a satisfait à la règle de cotation 5550(a)(2), qui exige un prix minimum de 1,00 $ par action pendant au moins 10 sessions de trading consécutives. Ce développement garantit la continuité de la cotation de Monopar à la bourse Nasdaq, préservant ainsi sa visibilité et son accès aux marchés de capitaux. Le statut de conformité est important pour les efforts continus de l'entreprise dans le développement de traitements innovants contre le cancer.
Monopar Therapeutics (Nasdaq: MNPR), ein klinisches radiopharmazeutisches Unternehmen, hat die Konformität mit den Mindestpreisvorgaben von Nasdaq wiedererlangt. Das Unternehmen erhielt von Nasdaq die Mitteilung, dass es die Listungsregel 5550(a)(2) erfüllt hat, die einen Mindestpreis von 1,00 $ pro Aktie für mindestens 10 aufeinanderfolgende Handelssitzungen verlangt. Diese Entwicklung sichert die fortdauernde Listung von Monopar an der Nasdaq-Börse und erhält dessen Sichtbarkeit und Zugang zu den Kapitalmärkten. Der Konformitätsstatus ist wichtig für die laufenden Bemühungen des Unternehmens bei der Entwicklung innovativer Krebsbehandlungen.
- Regained compliance with Nasdaq's minimum bid price requirement
- Maintained listing on Nasdaq stock exchange
- Ensured continued visibility and access to capital markets
- None.
WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
What Nasdaq rule did Monopar Therapeutics (MNPR) comply with on August 27, 2024?
How long did Monopar Therapeutics (MNPR) maintain a closing bid price above $1.00 to regain compliance?
What is the impact of regaining Nasdaq compliance for Monopar Therapeutics (MNPR)?
